Bone loss in ankylosing spondylitis: Can we put the puzzle together?

Journal of Rheumatology

Volumn 32, Issue 7, 2005, Pages 1184-1185

  Wendling, Daniel ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17 RECEPTOR; INTERLEUKIN RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; BONE DENSITY; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; HUMAN; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

BONE DISEASES, METABOLIC; HUMANS; OSTEOPOROSIS; SPONDYLITIS, ANKYLOSING;

EID: 22244493235     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Toussirot E, Wendung D. Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 2000; 18 Suppl 21:S16-S20.
2. El Maghraoui A. Osteoporosis and ankylosing spondylitis. Joint Bone Spine 2004;71:291-5.
3. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004;31:2236-41.
4. Vosse D, Feldtkeller E, Erlendsson J, Geusens P, Van Der Linden S. Clinical vertebral fractures in patients with ankylosing spondylitis. J Rheumatol 2004;31:1981-5.
5. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently in ankylosing spondylitis patients with syndesmophytes. J Rheumatol 2005;32:1290-8.
6. Jansen TLT, Aarts MHM, Zanen S, Bruyn GAW. Risk assessment for osteoporosis by quantitative ultrasound of the heel in ankylosing spondylitis. Clin Exp Rheumatol 2003;21:599-604.
7. Bessant R, Harris C, Keat A. Audit of the diagnosis, assessment, and treatment of osteoporosis in patients with ankylosing spondylitis. J Rheumatol 2003;30:779-82.
8. Gilgil E, Kaçar C, Tuncer T, Bütün B. The association of syndesmophytes with vertebral bone mineral density in patients with ankylosing spondylitis. J Rheumatol 2005;32:292-4.
9. Lange U, Kluge A, Strunk J, Teichmann J, Bachmann G. Ankylosing spondylitis and bone mineral density - what is the ideal tool for measurement? Rheumatology Int 2005; published online: 5 Nov 2004.
10. Szejnfeld VL, Monier-Faugere MC, Bognar BJ, Ferraz MB, Malluche HH. Systemic osteopenia and mineralization defect in patients with ankylosing spondylitis. J Rheumatol 1997;24:683-8.
11. Obermayer-Pietsch BM, Lange U, Tauber G, et al. Vitamin D receptor initiation codon polymorphism, bone density and inflammatory activity of patients with ankylosing spondylitis. Osteoporosis Int 2003;14:995-1000.
12. Walsh NC, Gravallese M. Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr Opin Rheumatol 2004;16:419-27.
13. Lange U, Teichmann J, Stracke H. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 2000;5:507-11.
14. Graffen SL. Biology of recently discovered cytokines: interleukin-17 - a unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Res Ther 2004;6:240-7.
15. Lubberts E, Van Der Bersselaar L, Oppers-Walgreen B, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003;170:2655-62.
16. Briot K, Garnero P, Le Henaff A, Dougados M, Roux C. Body weight, body composition and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor-α therapy. Ann Rheum Dis 2005; published online January 7, 2005: doi: 10.1136/ard.2004.028670